HIGHLIGHTS
- who: Huijing Dong et al. from the Beijing University of Chinese Medicine, Beijing, China have published the Article: Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis, in the Journal: Journal of Oncology of 30/Nov/2022
- what: The authors found that ICIs showed higher ORR (25.80% vs. 18.10%) and DCR (66.22% vs. 58.74%) in patients with hepatitis B/C than those without infection.
- how: If an update of the same population data was given the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.